CWBR - CohBar - The Pioneer In Mitochondrial Drugs
CohBar (CWBR) is a development-stage biotech company focused on drugs based on mitochondria-based therapeutics (MBTs), an emerging class of drugs with the potential to treat a wide range of diseases associated with aging and metabolic dysfunction, including non-alcoholic steatohepatitis ((NASH)), obesity, type 2 diabetes, cancer, atherosclerosis, cardiovascular disease, fibrosis, neurodegenerative diseases such as Alzheimer's disease, and eventually aging itself. The company has applied for over 65 patents.
The stock is down 80% from its all-time high in January 2018, yet it has moved its lead drug into human clinical trials and has several